WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year

About this update from Wuxi Biologics (cayman) Inc.

SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA) A List for the second consecutive year. The recognition highlights the company's leadership in engaging suppliers on climate-related issues and reflects its strong performance in governance, target-setting, Scope 3 emissions disclosure, and value chain engagement. The company has also been recognized on CDP's Climate Change and Water Security A Lists, further demonstrating its strong performance in sustainability. The CDP SEA A List represents the highest level of performance in corporate environmental transparency and supply chain climate action. In 2025, more than 23,000 companies, cities, states and regions disclosed environmental data through CDP.WuXi Biologics actively engages with suppliers to address Scope 3 emissions through a structured approach, including risk assessments, audits, training, incentive programs, as well as Scope 3 data disclosure and target tracking, driving continuous improvement across the value chain and supporting strong supplier engagement performance.The company's climate strategy is underpinned by Science Based Targets initiative (SBTi)-approved near-term and net-zero greenhouse gas (GHG) emissions reduction targets, including a commitment to achieve net-zero emissions across the value chain by 2050.Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are honored to be named to CDP's Supplier Engagement Assessment A List for the second consecutive year. This achievement reflects our continued efforts to strengthen supplier collaboration and enhance value chain sustainability. As a global leader in Green CRDMO, we remain committed to working closely with all stakeholders to drive long-term sustainable growth."Over the years, WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; a listing in Dow Jones Best‑in‑Class World Index and Emerging Markets Index; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Goo...

View stock analysis, news, and events for Wuxi Biologics (cayman) Inc.